Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Matthew R. Sydes"'
Autor:
Gerhardt Attard, Laura Murphy, Noel W Clarke, Ashwin Sachdeva, Craig Jones, Alex Hoyle, William Cross, Robert J Jones, Christopher C Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Clare Gilson, Hannah Rush, Hoda Abdel-Aty, Claire L Amos, Claire Murphy, Simon Chowdhury, Zafar Malik, J Martin Russell, Nazia Parkar, Cheryl Pugh, Carlos Diaz-Montana, Carmel Pezaro, Warren Grant, Helen Saxby, Ian Pedley, Joe M O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir H Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D Brown, Yatin Jain, David P Dearnaley, Malcolm D Mason, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes, Louise C Brown, Mahesh K B Parmar, Nicholas D James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Ami Sabharwal, Uschi Hofmann, Robert Dealey, Neil McPhail, Robert Brierly, Lisa Capaldi, Norma Sidek, Peter Whelan, Peter Robson, Alison Falconer, Sarah Rudman, Sindu Vivekanandan, Vinod Mullessey, Maria Vilarino-Varela, Vincent Khoo, Karen Tipples, Mehran Afshar, Patryk Brulinski, Vijay Sangar, Clive Peedell, Ashraf Azzabi, Peter Hoskin, Viwod Mullassery, Santhanam Sundar, Yakhub Khan, Ruth Conroy, Andrew Protheroe, Judith Carser, Paul Rogers, Kathryn Tarver, Stephanie Gibbs, Mohammad Muneeb Khan, Mohan Hingorani, Simon Crabb, Manal Alameddine, Neeraj Bhalla, Robert Hughes, John Logue, Darren Leaning, Salil Vengalil, Daniel Ford, Georgina Walker, Ahmed Shaheen, Omar Khan, Andrew Chan, Imtiaz Ahmed, Serena Hilman, Ian Sayers, Ashok Nikapota, David Bloomfield, Tim Porter, Joji Joseph, Cyrill Rentsch, Ricardo Pereira Mestre, Enrico Roggero, Jörg Beyer, Markus Borner, Raeto Strebel, Dominik Berthold, Daniel Engeler, Hubert John, Razvan Popescu, Donat Durr
Publikováno v:
STAMPEDE investigators, Attard, G, Murphy, L, Clarke, N W, Sachdeva, A, Jones, C, Hoyle, A, Cross, W, Jones, R J, Parker, C C, Gillessen, S, Cook, A, Brawley, C, Gilson, C, Rush, H, Abdel-Aty, H, Amos, C L, Murphy, C, Chowdhury, S, Malik, Z, Russell, J M, Parkar, N, Pugh, C, Diaz-Montana, C, Pezaro, C, Grant, W, Saxby, H, Pedley, I, O'Sullivan, J M, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzouebi, M, Parikh, O, Robinson, A, Montazeri, A H, Wylie, J, Zarkar, A, Cathomas, R, Brown, M D, Jain, Y, Dearnaley, D P, Mason, M D, Gilbert, D, Langley, R E & Millman, R 2023, ' Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol ', Lancet Oncology, vol. 24, no. 5, pp. 443-456 . https://doi.org/10.1016/S1470-2045(23)00148-1
Attard, G, Murphy, L, Clarke, N W, Sachdeva, A, Jones, C, Hoyle, A, Cross, W, Jones, R J, Parker, C C, Gillessen, S, Cook, A, Brawley, C, Gilson, C, Rush, H, Abdel-Aty, H, Amos, C L, Murphy, C, Chowdhury, S, Malik, Z, Russell, J M, Parkar, N, Pugh, C, Diaz-Montana, C, Pezaro, C, Grant, W, Saxby, H, Pedley, I, O'Sullivan, J M, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzouebi, M, Parikh, O, Robinson, A, Montazeri, A H, Wylie, J, Zarkar, A, Cathomas, R, Brown, M D, Jain, Y, Dearnaley, D P, Mason, M D, Gilbert, D, Langley, R E & Millman, R 2023, ' Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy : final results from two randomised phase 3 trials of the STAMPEDE platform protocol ', The Lancet. Oncology, vol. 24, no. 5, pp. 443-456 . https://doi.org/10.1016/S1470-2045(23)00148-1
Attard, G, Murphy, L, Clarke, N W, Sachdeva, A, Jones, C, Hoyle, A, Cross, W, Jones, R J, Parker, C C, Gillessen, S, Cook, A, Brawley, C, Gilson, C, Rush, H, Abdel-Aty, H, Amos, C L, Murphy, C, Chowdhury, S, Malik, Z, Russell, J M, Parkar, N, Pugh, C, Diaz-Montana, C, Pezaro, C, Grant, W, Saxby, H, Pedley, I, O'Sullivan, J M, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzouebi, M, Parikh, O, Robinson, A, Montazeri, A H, Wylie, J, Zarkar, A, Cathomas, R, Brown, M D, Jain, Y, Dearnaley, D P, Mason, M D, Gilbert, D, Langley, R E & Millman, R 2023, ' Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy : final results from two randomised phase 3 trials of the STAMPEDE platform protocol ', The Lancet. Oncology, vol. 24, no. 5, pp. 443-456 . https://doi.org/10.1016/S1470-2045(23)00148-1
Background: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-t
Autor:
Ruth E Langley, David P. Dearnaley, H. Rush, Silke Gillessen, Mahesh K. B. Parmar, Andrew Protheroe, Robin Millman, Shaun Tolan, Zaf Malik, Peter Hoskin, Christopher D. Brawley, Duncan C. Gilbert, Simon Chowdhury, Noel W. Clarke, Sarah Rudman, Nicholas D. James, Carla Perna, Neil McPhail, J. Martin Russell, Robert Jones, John Wagstaff, Adrian Cook, Gerhardt Attard, Joanna Gale, Salil Vengalil, Emma Gray, Alison Birtle, David Gareth Fackrell, Jacob Tanguay, Matthew R. Sydes, Archie Macnair, Joe M. O'Sullivan, Chris Parker, Alicia K. Morgans, Laura Murphy, David Matheson, C. Pugh
Publikováno v:
J Clin Oncol
PURPOSE Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Th
Autor:
Nicholas D James, Fiona C Ingleby, Noel W Clarke, Claire L Amos, Gerhardt Attard, Christopher D Brawley, Simon Chowdhury, William Cross, David P Dearnaley, Duncan C Gilbert, Silke Gillessen, Robert J Jones, Ruth E Langley, Archie Macnair, Zafar I Malik, Malcolm D Mason, David J Matheson, Robin Millman, Chris C Parker, Hannah L Rush, J Martin Russell, Carly Au, Alastair W S Ritchie, Ricardo Pereira Mestre, Imtiaz Ahmed, Alison J Birtle, Susannah J Brock, Prantik Das, Victoria A Ford, Emma K Gray, Robert J Hughes, Caroline B Manetta, Duncan B McLaren, Ashok D Nikapota, Joe M O’Sullivan, Carla Perna, Clive Peedell, Andrew S Protheroe, Santhanam Sundar, Jacob S Tanguay, Shaun P Tolan, John Wagstaff, Jan B Wallace, James P Wylie, Anjali Zarkar, Mahesh K B Parmar, Matthew R Sydes
Publikováno v:
James, N D, Ingleby, F C, Clarke, N W, Amos, C L, Attard, G, Brawley, C D, Chowdhury, S, Cross, W, Dearnaley, D P, Gilbert, D C, Gillessen, S, Jones, R J, Langley, R E, Macnair, A, Malik, Z I, Mason, M D, Matheson, D J, Millman, R, Parker, C C, Rush, H L, Russell, J M, Au, C, Ritchie, A W S, Mestre, R P, Ahmed, I, Birtle, A J, Brock, S J, Das, P, Ford, V A, Gray, E K, Hughes, R J, Manetta, C B, McLaren, D B, Nikapota, A D, O'Sullivan, J M, Perna, C, Peedell, C, Protheroe, A S, Sundar, S, Tanguay, J S, Tolan, S P, Wagstaff, J, Wallace, J B, Wylie, J P, Zarkar, A, Parmar, M K B & Sydes, M R 2022, ' Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial ', JNCI Cancer Spectrum, vol. 6, no. 4, pkac043 . https://doi.org/10.1093/jncics/pkac043
Background STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy. We report long-term results for non-metastatic patients using, as primary outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00eff5f0fa14f1899d76357eb1c4d2a4
https://eprints.gla.ac.uk/276500/1/276500.pdf
https://eprints.gla.ac.uk/276500/1/276500.pdf
Autor:
Emily, Grist, Stefanie, Friedrich, Christopher, Brawley, Larissa, Mendes, Marina, Parry, Adnan, Ali, Aine, Haran, Alex, Hoyle, Claire, Gilson, Sharanpreet, Lall, Leila, Zakka, Carla, Bautista, Alex, Landless, Karolina, Nowakowska, Anna, Wingate, Daniel, Wetterskog, A M Mahedi, Hasan, Nafisah B, Akato, Malissa, Richmond, Sofeya, Ishaq, Nik, Matthews, Anis A, Hamid, Christopher J, Sweeney, Matthew R, Sydes, Daniel M, Berney, Stefano, Lise, Mahesh K B, Parmar, Noel W, Clarke, Nicholas D, James, Paolo, Cremaschi, Louise C, Brown, Gerhardt, Attard
Publikováno v:
Genome medicine. 14(1)
Background Genomic copy number alterations commonly occur in prostate cancer and are one measure of genomic instability. The clinical implication of copy number change in advanced prostate cancer, which defines a wide spectrum of disease from high-ri
Autor:
Caroline S. Clarke, Rachael M. Hunter, Andrea Gabrio, Christopher D. Brawley, Fiona C. Ingleby, David P. Dearnaley, David Matheson, Gerhardt Attard, Hannah L. Rush, Rob J. Jones, William Cross, Chris Parker, J. Martin Russell, Robin Millman, Silke Gillessen, Zafar Malik, Jason F. Lester, James Wylie, Noel W. Clarke, Mahesh K. B. Parmar, Matthew R. Sydes, Nicholas D. James
Publikováno v:
PLOS ONE, 17(6):e0269192. Public Library of Science
Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy. Our objective was to determine the value for money to the English Na
Publikováno v:
European Urology Focus. 5:125-133
Context Androgen deprivation therapy (ADT) is the standard of care for men with metastatic hormone-sensitive prostate cancer (HSPC) and a potential treatment option in those with prostate-specific antigen relapse after local therapy. Based on promisi
Autor:
Malcolm David Mason, Robin Millman, Alison Birtle, Duncan McLaren, David Matheson, Stephanie Gibbs, John Graham, Prabir Chakraborti, Mahesh K. B. Parmar, Joanna Gale, Matthew S. Simms, Melissa Gannon, John Wagstaff, Anna T.H. Tran, J. Martin Russell, Robert Hughes, Joe M. O'Sullivan, Santhanam Sundar, Omi Parikh, Beth Woods, Mymoona Alzouebi, Audrey Cook, Richard Cathomas, Angus Robinson, Eleftherios Sideris, Robert Jones, Robert W. Laing, Susannah Brock, Clive Peedell, Narayanan Srihari, Chris Parker, Shaun Tolan, Gerhardt Attard, Nicholas D. James, Matthew R. Sydes, Alastair W. S. Ritchie, Andrew Protheroe, Mark Sculpher, William Cross, David Tsang, George N. Thalmann, Rajaguru Srinivasan, John Staffurth, David P. Dearnaley
Publikováno v:
Woods, B S, Sideris, E, Sydes, M R, Gannon, M R, Parmar, M K B, Alzouebi, M, Attard, G, Birtle, A J, Brock, S, Cathomas, R, Chakraborti, P R, Cook, A, Cross, W R, Dearnaley, D P, Gale, J, Gibbs, S, Graham, J D, Hughes, R, Jones, R J, Laing, R, Mason, M D, Matheson, D, McLaren, D B, Millman, R, O'Sullivan, J M, Parikh, O, Parker, C C, Peedell, C, Protheroe, A, Ritchie, A W S, Robinson, A, Russell, J M, Simms, M S, Srihari, N N, Srinivasan, R, Staffurth, J N, Sundar, S, Thalmann, G N, Tolan, S, Tran, A T H, Tsang, D, Wagstaff, J, James, N D & Sculpher, M J 2018, ' Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness ', European urology oncology, vol. 1, no. 6, pp. 449-458 . https://doi.org/10.1016/j.euo.2018.06.004
European Urology Oncology
European Urology Oncology
Background Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs fai
Autor:
Deepika Reddy, John Staffurth, Chris Dobbs, Emily Day, Manit Arya, Hashim U. Ahmed, Stuart McCracken, Mark Emberton, Matthew R. Sydes, A T Prevost, Mathias Winkler, Tim Dudderidge, Francesca Fiorentino, Taimur T. Shah
Introduction Focal therapy (FT) targets individual areas of cancer within the prostate, providing oncological control with minimal side-effects. Early evidence demonstrates encouraging short-medium-term outcomes. With no randomized controlled trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca44ec45aca8908075410a9be26ace5e
Autor:
Janet E. Brown, J.M. Russell, Hassan Douis, Adrian Cook, Matthew R. Sydes, David Matheson, Narayanan Srihari, Alex Hoyle, Matthew S. Simms, A. Nikapota, Anjali Zarkar, Christopher D. Brawley, F.C. Ingleby, Noel W. Clarke, J. Calvert, John Wagstaff, Duncan C. Gilbert, Gerhardt Attard, Jacob Tanguay, A.W.S. Ritchie, Adnan Ali, Ruth E Langley, Andrew Protheroe, Aurelius Omlin, H. Rush, Anna Lydon, David P. Dearnaley, Malcolm David Mason, James D. Wylie, Silke Gillessen, Simon Chowdhury, L. Capaldi, Sharon Beesley, Joe M O'Sullivan, Mona Parmar, Omi Parikh, Joanna Gale, Jan Wallace, S. Rudman, Chris Parker, Alison Birtle, Archie Macnair, Claire Amos, Stephanie Gibbs, Robin Millman, Robert Jones, Zafar Malik, William Cross, Nicholas D. James, Shaun Tolan
Publikováno v:
STAMPEDE Investigators 2019, ' Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial ', Annals of Oncology . https://doi.org/10.1093/annonc/mdz396
Annals of Oncology
Annals of Oncology
Background\ud \ud STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae50219cab2735395675e6bd870c6e64
https://doi.org/10.1093/annonc/mdz396
https://doi.org/10.1093/annonc/mdz396
Autor:
Noel W. Clarke, Duncan C. Gilbert, Ruth E Langley, Trinh Duong, Anna Bara, Matthew R. Sydes, Paul D. Abel, Max Parmar, Nicholas D. James
Publikováno v:
BJU international. 121(5)
Androgen deprivation therapy (ADT) remains a cornerstone of the management of prostate cancer. The addition of ADT to radiotherapy improves disease-free and overall survival in the locally advanced setting and ADT forms the backbone onto which additi